Unknown

Dataset Information

0

Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.


ABSTRACT: Purpose: Pediatric glioblastoma multiforme (pGBM) is a highly aggressive tumor in need of novel therapies. Our objective was to demonstrate the therapeutic efficacy of MLN8237 (alisertib), an orally available selective inhibitor of Aurora A kinase (AURKA), and to evaluate which in vitro model system (monolayer or neurosphere) can predict therapeutic efficacy in vivoExperimental Design: AURKA mRNA expressions were screened with qRT-PCR. In vitro antitumor effects were examined in three matching pairs of monolayer and neurosphere lines established from patient-derived orthotopic xenograft (PDOX) models of the untreated (IC-4687GBM), recurrent (IC-3752GBM), and terminal (IC-R0315GBM) tumors, and in vivo therapeutic efficacy through log rank analysis of survival times in two models (IC-4687GBM and IC-R0315GBM) following MLN8237 treatment (30 mg/kg/day, orally, 12 days). Drug concentrations in vivo and mechanism of action and resistance were also investigated.Results: AURKA mRNA overexpression was detected in 14 pGBM tumors, 10 PDOX models, and 6 cultured pGBM lines as compared with 11 low-grade gliomas and normal brains. MLN8237 penetrated into pGBM xenografts in mouse brains. Significant extension of survival times were achieved in IC-4687GBM of which both neurosphere and monolayer were inhibited in vitro, but not in IC-R0315GBM of which only neurosphere cells responded (similar to IC-3752GBM). Apoptosis-mediated MLN8237 induced cell death, and the presence of AURKA-negative and CD133+ cells appears to have contributed to in vivo therapy resistance.Conclusions: MLN8237 successfully targeted AURKA in a subset of pGBMs. Our data suggest that combination therapy should aim at AURKA-negative and/or CD133+ pGBM cells to prevent tumor recurrence. Clin Cancer Res; 24(9); 2159-70. ©2018 AACR.

SUBMITTER: Kogiso M 

PROVIDER: S-EPMC6052861 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.

Kogiso Mari M   Qi Lin L   Braun Frank K FK   Injac Sarah G SG   Zhang Linna L   Du Yuchen Y   Zhang Huiyuan H   Lin Frank Y FY   Zhao Sibo S   Lindsay Holly H   Su Jack M JM   Baxter Patricia A PA   Adesina Adekunle M AM   Liao Debra D   Qian Mark G MG   Berg Stacey S   Muscal Jodi A JA   Li Xiao-Nan XN  

Clinical cancer research : an official journal of the American Association for Cancer Research 20180220 9


<b>Purpose:</b> Pediatric glioblastoma multiforme (pGBM) is a highly aggressive tumor in need of novel therapies. Our objective was to demonstrate the therapeutic efficacy of MLN8237 (alisertib), an orally available selective inhibitor of Aurora A kinase (AURKA), and to evaluate which <i>in vitro</i> model system (monolayer or neurosphere) can predict therapeutic efficacy <i>in vivo</i><b>Experimental Design:</b> AURKA mRNA expressions were screened with qRT-PCR. <i>In vitro</i> antitumor effect  ...[more]

Similar Datasets

| S-EPMC2874079 | biostudies-literature
| S-EPMC3215888 | biostudies-literature
| S-EPMC7059858 | biostudies-literature
| S-EPMC4468408 | biostudies-literature
| S-EPMC3297687 | biostudies-literature
| S-EPMC6172479 | biostudies-literature
| S-EPMC2892955 | biostudies-literature
| S-EPMC4171625 | biostudies-literature
| S-EPMC3792566 | biostudies-literature
| S-EPMC4975626 | biostudies-literature